Sulphur mustard (SM) is a powerful blister-causing alkylating chemical warfare agent used by Iraqi forces against Iran. One of the known complications of mustard gas inhalation is mustard lung which is discussed as a phenotype of chronic obstructive pulmonary disease (COPD). In this complication, there are clinical symptoms close to COPD with common etiologies, such as in smokers. Based on information gradually obtained by conducting the studies on mustard lung patients, systemic symptoms along with pulmonary disorders have attracted the attention of researchers. Changes in serum levels of inflammatory markers, such as C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α), nuclear factor κB (NF-κB), matrix metalloproteinases (MMPs), interleukin (IL), chemokines, selectins, immunoglobulins, and signs of imbalance in oxidant-antioxidant system at serum level, present the systemic changes in these patients. In addition to these, reports of extra-pulmonary complications, such as osteoporosis and cardiovascular disease are also presented. In this study, the chance of developing the systemic nature of this lung disease have been followed on using the comparative study of changes in the mentioned markers in mustard lung and COPD patients at stable phases and the mechanisms of pathogenesis and phenomena, such as airway remodeling in these patients.
Adamson IY, Bowden DH. (1974). The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol77: 185–197.
Agin K. (2004). Comparison of prevalence of osteoporosis in patients with asthma following chemical injury in patients with asthma Sulfur-mustard non chemical victims. Mil Res J4: 419–422.
Agusti A, Soriano JB. (2008). COPD as a systemic disease. COPD: Journal of Chronic Obstructive Pulmonary Disease5: 133–138.
Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S. (2004). Analysis of systemic biomarkers in COPD patients. Copd1: 155–164.
Anderson GP. (2006). COPD, asthma and C-reactive protein. Eur Respir J27: 874–876.
Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, Marallu HG, Mazloomi M, Balali-Mood M. (2009). Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Hum Exp Toxicol28: 739–745.
Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, Ghanei M, Basiri R. (2010). Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis5: 335–340.
Balali-Mood M, Afshari R, Zojaji R, Kahrom H, Kamrani M, Attaran D, Mousavi SR, Zare GA. (2011). Delayed toxic effects of sulfur mustard on respiratory tract of Iranian veterans. Hum Exp Toxicol30(9): 1141–1149.
Barnes PJ, Celli BR. (2009). Systemic manifestations and comorbidities of COPD. Eur Respir J33: 1165–1185.
Barnes TC, Anderson ME, Moots RJ. (2011). The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol2011: 721608.
Batra S, Balamayooran G, Sahoo MK. (2011). Nuclear factor-kappaB: a key regulator in health and disease of lungs. Arch Immunol Ther Exp (Warsz)59: 335–351.
Bayat N, Aslani J. (2010). Comparing the bone mineral density in chemical injures and non-chemical asmatic patients. Trauma Monthly2011: 105–110.
Biskobing DM. (2002). COPD and osteoporosis. Chest121: 609–620.
Blackwell TS, Christman JW. (1997). The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol17: 3–9.
Calderon TM, Berman JW. (2005). Overview and history of chemokines and their receptors. Current Topics in Membranes55: 1–47.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, investigators T. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med356: 775–789.
Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H, Sterrett A, Carney G, Murphy N, Huang Y, Valeriano J, Vasey FB. (2008). The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med102: 1165–1172.
Comhair SA, Bhathena PR, Dweik RA, Kavuru M, Erzurum SC. (2000). Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response. Lancet355: 624.
Comhair SA, Erzurum SC. (2002). Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol283: L246–255.
Dahl M, Nordestgaard BG. (2009). Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis4: 157–167.
Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. (2007). C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine175: 250–255.
Dayhimi I, Bahar K, Eliasy H. (1988). The effect of sulfur mustard gas (SMG) on the immune system. In: The First International Medical Congress on Chemical Warfare Agents in Iran Mashhad, Iran: Mashhad University of Medical Sciences.
de Moraes MR, da Costa AC, Correa Kde S, Junqueira-Kipnis AP, Rabahi MF. (2014). Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. Int J Chron Obstruct Pulmon Dis9: 735–743.
Denk A, Wirth T, Baumann B. (2000). NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev11: 303–320.
Egeblad M, Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer2: 161–174.
Ekstrand-Hammarstrom B, Wigenstam E, Bucht A. (2011). Inhalation of alkylating mustard causes long-term T cell-dependent inflammation in airways and growth of connective tissue. Toxicology280: 88–97.
Emad A, Rezaian GR. (1999). Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest115: 1346–1351.
Evison D, Hinsley D, Rice P. (2002). Regular review: chemical weapons. BMJ: British Medical Journal324: 332.
Fakhraddin F, Reza SA, Yahya D, Akbar KZA, Mahdi C. (1999). Does Sulfur Mustard (HD) have an accelerating effect on CABG in HD-exposed people? Is it a link? Medical Science and Technology48: RA11–RA13.
Firoozabadi MD, Shahriary A, Rahmani H. (2017). Mustard lung anesthesia; general anesthesia for patients with chronic obstructive pulmonary disease due to sulphur mustard exposure. Minerva Pneumol56: 254–257.
Fooladi AAI, Nourani MR, Yazdani S. (2012). Lung and Systemic Inflammation in COPD: INTECH Open Access Publisher.
Foronjy RF, Okada Y, Cole R, D’Armiento J. (2003). Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol284: L727–737.
Fukuda Y, Ishizaki M, Kudoh S, Kitaichi M, Yamanaka N. (1998). Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest78: 687–698.
Geddes EL, Reid WD, Crowe J, O’Brien K, Brooks D. (2005). Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med99: 1440–1458.
Ghanei M, Adibi I, Farhat F, Aslani J. (2008). Late respiratory effects of sulfur mustard: how is the early symptoms severity involved? Chronic respiratory disease5: 95–100.
Ghanei M, Harandi AA. (2007). Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol19: 451–456.
Ghasemi H, Ghazanfari T, Babaei M, Soroush MR, Yaraee R, Ghassemi-Broumand M, Javadi MA, Foroutan A, Mahdavi MR, Shams J, Pourfarzam S, Moaiedmohseni S, Nadoushan MR, Owlia P, Panahi Y, Hassan ZM, Faghihzadeh S. (2008). Long-term ocular complications of sulfur mustard in the civilian victims of Sardasht, Iran. Cutan Ocul Toxicol27: 317–326.
Ghasemi H, Ghazanfari T, Yaraee R, Ghassemi-Broumand M, Soroush MR, Pourfarzam S, Masdari Z, Faghihzadeh S, Babaei M, Javadi MA. (2009). Evaluation of relationship between the serum levels of inflammatory mediators and ocular injuries induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol9(13–14): 1494–1498.
Ghasemi H, Mostafaie A, Yaraee R, Hassan ZM, Rezaei A, Mahmoudi M, Faghihzadeh S, Soroush MR, Ardestani SK, Babaei M, Jalali-Nadoushan M, Khamesipour A, Ghassemi-Broumand M, Ghazanfari T. (2013). Association of serum immunoglobulins levels and eye injuries in sulfur mustard exposed: Sardasht-Iran Cohort Study. Int Immunopharmacol17: 944–951.
Ghazanfari T, Mostafaie A, Yaraee R, Pourfarzam S, Faghihzadeh S, Rezaei A, Mahmoudi M, Vaez-Mahdavi MR, Moaiedmohseni S, Soroush MR, Naghizadeh MM, Faghihzadeh E, Hassan ZM. (2013). Are serum levels of immunoglobulin classes and IgG subclasses involved in delayed pulmonary complications induced by sulfur mustard? Sardasht-Iran Cohort Study. Int Immunopharmacol17: 936–943.
Ghazanfari T, Yaraee R, Kariminia A, Ebtekar M, Faghihzadeh S, Vaez-Mahdavi MR, Rezaei A, Vojgani M, Soroush MR, Kermani-Jalilvand A. (2009). Alterations in the serum levels of chemokines 20years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol9(13–14): 1471–6.
Ghotbi L, Hassan Z. (2002). The immunostatus of natural killer cells in people exposed to sulfur mustard. Int Immunopharmacol2: 981–985.
Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. (2009). Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J34: 209–218.
Groot Kormelink T, Pardo A, Knipping K, Buendia-Roldan I, Garcia-de-Alba C, Blokhuis BR, Selman M, Redegeld FA. (2011). Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One6: e25392.
Hammad DR, Elgazzar AG, Essawy TS, El Sameie SAA. (2015). Evaluation of serum interleukin-1 beta as an inflammatory marker in COPD patients. Egyptian Journal of Chest Diseases and Tuberculosis64: 347–352.
Hassan ZM, Ebtekar M, Ghanei M, Taghikhani M, Noori Daloii MR, Ghazanfari T. (2006). Immunobiological consequences of sulfur mustard contamination. Iran J Allergy Asthma Immunol5: 101–108.
Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell132: 344–362.
Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. (2005). Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol17: 587–592.
Heidari A, Sheikhi MA, Rahmani H. (2016). Inflammatory status of Non-Smoker Sulphur Mustard exposed Patient with Cancer candidate for Coronary artery bypass grafting Surgery. Int J Pharm Res Allied Sci5: 196–198.
Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. (2009). Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med103(8): 1231–1238.
Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. (2006). Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med174(8): 867–874.
Husain K, Dube SN, Sugendran K, Singh R, Das Gupta S, Somani SM. (1996). Effect of topically applied sulphur mustard on antioxidant enzymes in blood cells and body tissues of rats. J Appl Toxicol16: 245–248.
Chauhan S, Gupta MK, Goyal A, Dasgupta DJ. (1990). Alterations in immunoglobulin & complement levels in chronic obstructive pulmonary disease. Indian J Med Res92: 241–245.
Chung KF. (2005). Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy4: 619–625.
Imani S, Panahi Y, Salimian J, Fu J, Ghanei M. (2015). Epigenetic: A missing paradigm in cellular and molecular pathways of sulfur mustard lung: a prospective and comparative study. Iran J Basic Med Sci18: 723–736.
Imanifooladi A A, Yazdani S, Nourani MR. (2010). The role of nuclear factor-kappaB in inflammatory lung disease. Inflamm Allergy Drug Targets9(3): 197–205.
Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. (1999). Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest116: 1616–1624.
Irwin CR, Myrillas TT, Traynor P, Leadbetter N, Cawston TE. (2002). The role of soluble interleukin (IL)-6 receptor in mediating the effects of IL-6 on matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expression by gingival fibroblasts. J Periodontol73: 741–747.
Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. (2000). Neither IL-1 β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD. Respir Med94: 847–851.
Jorgensen NR, Schwarz P. (2008). Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med14: 122–127.
Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. (2008a). Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung186: 403–409.
Karadag F, Kirdar S, Karul AB, Ceylan E. (2008b). The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med19(2): 104–108.
Karbasi-Afshar R, Shahmari A, Madadi M, Poursaleh Z, Saburi A. (2013). Coronary angiography findings in lung injured patients with sulfur mustard compared to a control group. Ann Card Anaesth16: 188–192.
Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. (2003). Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med45(11): 1136–1143.
Kiani A, Mostafaie A, Shirazi FH, Ghazanfari T. (2013). Serum profiles of matrix metalloproteinases and their tissue inhibitors in long-term pulmonary complication induced by sulfur mustard: Sardasht-Iran Cohort Study (SICS). Int Immunopharmacol17(3): 964–967.
Kim H, Liu X, Kohyama T, Kobayashi T, Conner H, Abe S, Fang Q, Wen F-Q, Rennard SI. (2004). Cigarette smoke stimulates MMP-1 production by human lung fibroblasts through the ERK1/2 pathway. COPD1(1): 13–23.
Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. (2004). Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax59: 892–896.
Kopff M, Zakrzews ka I, Strzelczyk M, Klem J, Dubiecki W. (1993). Superoxide dismutase and catalase activity in psoriatic patients treated topically with ointment containing 2-chloroethyl-3-chloropropyl sulfide. Pol J Pharmacol46(5): 439–444.
Kraus VB, Stabler TV, Luta G, Renner JB, Dragomir AD, Jordan JM. (2007). Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage15(8): 966–971.
Krumbhaar EB, Krumbhaar HD. (1919). The Blood and Bone Marrow in Yelloe Cross Gas (Mustard Gas) Poisoning: Changes produced in the Bone Marrow of Fatal Cases. J Med Res40: 497–508.
Lahousse L, Loth DW, Joos GF, Hofman A, Leufkens HG, Brusselle GG, Stricker BH. (2013). Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther26: 212–217.
Lai Y, Liu X, Zeng Y, Zhang Y, Shen Y, Liu Y. (2012). Interleukin-8 induces the endothelial cell migration through the Rac1/RhoA-p38MAPK pathway. Cell51: 38MAPK.
Langen RC, Korn S H, Wouters EF. (2003). ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med35: 226–235.
Lari SM, Attaran D, Towhidi M. (2012). COPD Due to Sulfur Mustard (Mustard Lung): INTECH Open Access Publisher.
Laskin DL, Sunil VR, Laumbach RJ, Kipen HM. (2007). Inflammatory cytokines and lung toxicity. In: Cytokines in Human Health, pp 83–112: Springer.
Lee KY, Ho SC, Chan YF, Wang CH, Huang CD, Liu WT, Lin SM, Lo YL, Chang YL, Kuo LW, Kuo HP. (2012). Reduced nuclear factor-kappaB repressing factor: a link toward systemic inflammation in COPD. Eur Respir J40: 863–873.
Lehmann W, Edgar CM, Wang K, Cho TJ, Barnes GL, Kakar S, Graves DT, Rueger JM, Gerstenfeld LC, Einhorn TA. (2005). Tumor necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone36: 300–310.
Levitt JM, Lodhi IJ, Nguyen PK, Ngo V, Clift R, Hinshaw DB, Sweeney JF. (2003). Low-dose sulfur mustard primes oxidative function and induces apoptosis in human polymorphonuclear leukocytes. Int Immunopharmacol3: 747–756.
Ley K. (2003). The role of selectins in inflammation and disease. Trends Mol Med9: 263–268.
Littner MR. (2011). In the clinic. Chronic obstructive pulmonary disease. Ann Intern Med154: ITC4-1-ITC4-15; quiz ITC14-16.
MacNee W. (2005). Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc2: 50–60.
Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. (2005). Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol5: 1479–1485.
Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, Sin DD. (2008). Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J32: 1451–1457.
Miedema I, Feskens EJ, Heederik D, Kromhout D. (1993). Dietary determinants of long-term incidence of chronic nonspecific lung diseases. The Zutphen Study. Am J Epidemiol138: 37–45.
Mirbagher Ajorpaz N, Rezaei M. (2009). The Effects of pulmonary rehabilitation techniques on the clinical status of patients with moderate severity chronic obstructive pulmonary diseases (COPD) at University Hospitals of Isfahan in 2006–7. ZUMS Journal17: 1–12.
Mishra NC, Rir-sima-ah J, Grotendorst GR, Langley RJ, Singh SP, Gundavarapu S, Weber WM, Pena-Philippides JC, Duncan MR, Sopori ML. (2012). Inhalation of sulfur mustard causes long-term T cell-dependent inflammation: possible role of Th17 cells in chronic lung pathology. Int Immunopharmacol13: 101–108.
Moermans C, Heinen V, Nguyen M, Henket M, Sele J, Manise M, Corhay JL, Louis R. (2011). Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine56: 298–304.
Moin A, Ghazanfari T, Davoudi SM, Emadi N, Panahi Y, Hassan ZM, Soroush MR, Khateri S, Amini R, Naghizadeh MM. (2009). Long-term skin findings of sulfur mustard exposure on the civilians of Sardasht, Iran. Toxin Reviews28: 24–29.
Montano M, Sansores RH, Becerril C, Cisneros J, Gonzalez-Avila G, Sommer B, Ochoa L, Herrera I, Ramirez-Venegas A, Ramos C. (2014). FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. Respir Res15: 74.
Naghii MR. (2002). Sulfur mustard intoxication, oxidative stress, and antioxidants. Mil Med167: 573–575.
Nussbaumer-Ochsner Y, Rabe KF. (2011). Systemic manifestations of COPD. Chest139: 165–173.
O’Keeffe S, Gzel A, Drury R, Cullina M, Greally J, Finnegan P. (1991). Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J4: 932–936.
Paromov V, Suntres Z, Smith M, Stone WL. (2007). Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. J Burns Wounds7: e7.
Parvizpour F, Ghazanfari T, Salimi H, Faghihzadeh S, Yaraee R, Sharifnia Z, Soroosh MR, Naghizadeh MM. (2011). NFκB gene expression survey in peripheral blood cell of sardasht warfare agent victims 20 years after exposure to sulfur mustard. Tebe-E-Janbaz3(12): 38–47.
Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. (2007). Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax62: 595–601.
Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. (2006). C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax61: 23–28.
Pourfarzam S, Ghazanfari T, Merasizadeh J, Ghanei M, Azimi G, Araghizadeh H, Foroutan A, Shams J, Ghasemi H, Yaraee R. (2009a). Long-term pulmonary complications in sulfur mustard victims of Sardasht, Iran. Toxin Reviews28: 8–13.
Pourfarzam S, Ghazanfari T, Yaraee R, Ghasemi H, Hassan ZM, Faghihzadeh S, Ardestani SK, Kariminia A, Fallahi F, Soroush MR, Merasizadeh J, Mahlojirad M, Naghizadeh MM, Ghanei M. (2009b). Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol9: 1482–1488.
Pourfarzam S, Yaraee R, Hassan ZM, Yarmohammadi ME, Faghihzadeh S, Soroush MR, Fallahi F, Ardestani SK, Ebtekar M, Moaiedmohseni S, Naghizadeh MM, Ghasemi H, Shams J, Ghazanfari T. (2013). Chemokines, MMP-9 and PMN elastase in spontaneous sputum of sulfur mustard exposed civilians: Sardasht-Iran Cohort Study. Int Immunopharmacol17: 958–963.
Procianoy RS, Silveira RC. (2004). The role of sample collection timing on interleukin-6 levels in early-onset neonatal sepsis. J Pediatr (Rio J)80: 407–410.
Rahmani H, Javadi I, Shirali S. (2016). Respiratory complications due to sulfur mustard exposure. Int J Curr Res Acad Rev4(6): 143–149.
Rahmani H, Javadi I, Shirali S. (2017). Evaluation of serum levels of interleukin-6 and C-reactive protein in mustard lung patients and its relationship with pulmonary complications. Minerva Pneumologica56: 84–89.
Reid MB, Lannergren J, Westerblad H. (2002). Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med166: 479–484.
Rezaian GR, Emad A, Ghayumi MA, Rezaian S, Zare N. (2008). Exercise intolerance and chronotropic impairment-The long-term cardiovascular sequelae of mustard gas exposure: A paired-comparative study. Environ Toxicol Pharmacol26: 212–215.
Riahi-Zanjani B, Balali-Mood M, Mousavi SR, Karimi G, Sadeghi M, Shirmast E, Mahmoudi M. (2014). Serum cytokine profiles of Khorasan veterans 23 years after sulfur mustard exposure. Cytokine70: 161–164.
Rohani A, Akbari V, Moghadam FT. (2010). A case control study of cardiovascular health in chemical war disabled Iranian victims. Indian J Crit Care Med14: 109–112.
Rutten FH, Moons K G, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, Hoes AW. (2005). Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ331: 1379.
Sabourin CL, Danne MM, Buxton KL, Casillas RP, Schlager JJ. (2002). Cytokine, chemokine, and matrix metalloproteinase response after sulfur mustard injury to weanling pig skin. J Biochem Mol Toxicol16: 263–272.
Samaha HMS, Elsaid AR, NasrEldin E. (2015). Total serum IgE level in COPD patients. Egypt J Chest Dis Tuberc64(3): 573–577.
Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA. (2009). Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol29(4): 508–516.
Shahriary A, Mehrani H, Ghanei M, Parvin S. (2015). Comparative proteome analysis of peripheral neutrophils from sulfur mustard-exposed and COPD patients. J Immunotoxicol12: 132–139.
Shahriary A, Panahi Y, Shirali S, Rahmani H. (2017). Relationship of serum levels of interleukin 6, interleukin 8, and C-reactive protein with forced expiratory volume in first second in patients with mustard lung and chronic obstructive pulmonary diseases: systematic review and meta-analysis. Postepy Dermatol Alergol.34(3): 192–198.
Shahriary A, Rahmani H. (2017). Need to study of systemic markers changes in acute phase of respiratory complication due to sulfur mustard. Toxin Reviews36(3): 261–263.
Sheikhi MA, Rahmani H. (2016). Inflammatory statuses of non-smoker mustard lung patient candidate for coronary artery bypass grafting surgery. Int J Pharm Res Allied Sci5: 194–195.
Sheu B. (2008). Levels of neutrophils stimulation and matrix Metalloprotease in plasma of individuals with elevated blood pressure and acute/long-term exercise: ProQuest.
Shohrati M, Amini-Harandi A, Najafian B, Saburi A, Ghanei M. (2014a). The role of serum level of interleukin-6 i n severity of pulmonary complications of sulfur mustard injuries. Iran J Med Sci39: 382–386.
Shohrati M, Ghanei M, Shamspour N, Jafari M, Khasmakhi MNA. (2009). Extra cellular Superoxide Dismutase activity in lung injuries due to Sulfur Mustard. J Qazvin Uni Med Sci12: 5–11.
Shohrati M, Haji Hosseini R, Esfandiari MA, Najafian N, Najafian B, Golbedagh A. (2014b). Serum matrix metalloproteinase levels in patients exposed to sulfur mustard. Iran Red Crescent Med J16: e15129.
Shrivastava AK, Singh HV, Raizada A, Singh SK. (2015). C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal67(2): 89–97.
Schols AM. (2002). Pulmonary cachexia. Int J Cardiol85: 101–110.
Schumacher A, Liebers U, John M, Gerl V, Meyer M, Witt C, Wolff G. (2005). P-selectin glycoprotein ligand-1 (PSG L-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol142(2): 370–376.
Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Trevisan M. (2000). Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. CHEST Journal118: 656–664.
Schwartz J, Weiss ST. (1990). Dietary factors and their relation to respiratory symptoms the second national health and nutrition examination survey. Am J Epidemiol132(1): 67–76.
Schwartz J, Weiss ST. (1994). Relationship between dietary vitamin C intake and pulmonary function in the First National Health and Nutrition Examination Survey (NHANES I). Am J Clin Nutr59(1): 110–114.
Siebenlist U, Brown K, Claudio E. (2005). Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immuno l5: 435–445.
Sies H, Stahl W. (1995). Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am J Clin Nutr62(6 Suppl): 1315S–1321S.
Sin DD, Man SF. (2005). Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol83: 8–13.
Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. (2003). Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax58: 752–756.
Strachan DP, Cox BD, Erzinclioglu SW, Walters DE, Whichelow MJ. (1991). Ventilatory function and winter fresh fruit consumption in a random sample of British adults. Thorax46: 624–629.
Strieter RM, Kunkel SL, Bone RC. (1993). Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med21: S447–463.
Tabak C, Feskens EJ, Heederik D, Kromhout D, Menotti A, Blackburn HW. (1998). Fruit and fish consumption: a possible explanation for population differences in COPD mortality (The Seven Countries Study). Eur J Clin Nutr52: 819–825.
Tsuruta J, Sugisaki K, Dannenberg AM, Jr., Yoshimura T, Abe Y, Mounts P. (1996). The cytokines NAP-1 (IL-8), MCP-1, IL-1 beta, and GRO in rabbit inflammatory skin lesions produced by the chemical irritant sulfur mustard. Inflammation20: 293–318.
Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. (1996). The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis51: 145–152.
Visse R, Nagase H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res92: 827–839.
Voll-Aanerud M, Eagan TM, Wentzel-Larsen T, Gulsvik A, Bakke PS. (2008). Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med102: 399–406.
Wright JG, Christman JW. (2003). The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med2: 211–219.
Wu S, Chen P, Jiang X, Liu Z. (2005). C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban30(4): 444–446. [in Chinese]
Yaraee R, Ghazanfari T, Ebtekar M, Ardestani SK, Rezaei A, Kariminia A, Faghihzadeh S, Mostafaie A, Vaez-Mahdavi MR, Mahmoudi M. (2009a). Alterations in serum levels of inflammatory cytokines (TNF, IL-1alpha, IL-1beta and IL-1Ra) 20years after sulfur mustard exposure: Sardasht-Iran cohort study. Int Immunopharmacol9(13–14): 1466–1470.
Yaraee R, Ghazanfari T, Faghihzadeh S, Mostafaie A, Soroush MR, Inai K, Foroutan A, Shams J, Naghizadeh MM, Hassan Z M. (2009b). Alterations in the serum levels of soluble L, P and E-selectin 20years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int Immunopharmacol.9(13–14): 1477–1481.
Yaraee R, Hassan ZM, Pourfarzam S, Rezaei A, Faghihzadeh S, Ebtekar M, Soroush M-R, Ardestani SK, Kazemi H, Mahmoudi M. (2013). Fibrinogen and inflammatory cytokines in spontaneous sputum of sulfur-mustard-exposed civilians—Sardasht-Iran Cohort Study. Int Immunopharmacol17(3): 968–973.
Zakerimoghadam M, Tavasoli K, Nejad AK, Khoshkesht S. (2011). The effect of breathing exercises on the fatigue levels of patients with chronic obstructive pulmonary disease. Acta Med Indones43: 29–33.
Zandieh T, Marzban S, Tarabadi F, Ansari H. (1990). Defects of cell-mediated-immunity in mustard gas injury after years. Scand J Immunol32(4): 423.